Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Equity Income (2022 - 2025)

Corvus Pharmaceuticals has reported Equity Income over the past 4 years, most recently at -$707000.0 for Q4 2025.

  • Quarterly results put Equity Income at -$707000.0 for Q4 2025, up 67.48% from a year ago — trailing twelve months through Dec 2025 was -$2.0 million (up 38.76% YoY), and the annual figure for FY2025 was -$2.0 million, up 38.76%.
  • Equity Income for Q4 2025 was -$707000.0 at Corvus Pharmaceuticals, down from -$323000.0 in the prior quarter.
  • Over the last five years, Equity Income for CRVS hit a ceiling of $236000.0 in Q1 2024 and a floor of -$4.6 million in Q4 2022.
  • Median Equity Income over the past 4 years was -$953000.0 (2022), compared with a mean of -$1.3 million.
  • Biggest five-year swings in Equity Income: soared 113.63% in 2024 and later crashed 328.39% in 2025.
  • Corvus Pharmaceuticals' Equity Income stood at -$4.6 million in 2022, then soared by 69.73% to -$1.4 million in 2023, then tumbled by 54.84% to -$2.2 million in 2024, then skyrocketed by 67.48% to -$707000.0 in 2025.
  • The last three reported values for Equity Income were -$707000.0 (Q4 2025), -$323000.0 (Q3 2025), and -$389000.0 (Q2 2025) per Business Quant data.